J&J Pauses All Trials Evaluating COVID-19 Vax Candidate
By Contract Pharma Staff | 10.16.20
Temporarily pauses further dosing in all COVID-19 vaccine candidate trials to investigate an an unexplained illness.
Study pauses are not uncommon in clinical trials and are often resolved.
The Phase III ENSEMBLE trial of its Janssen COVID-19 vaccine candidate JNJ-78436735 involves an anticipated 60,000 adults in multiple countries, testing the safety and efficacy of a single dose versus a placebo in preventing COVID-19. A two-dose regimen is being tested in a separate trial.